KeyCorp lifts ResMed price target to $277
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
KeyCorp raised its ResMed (NYSE:RMD) price target to $277 from $267 while keeping an overweight rating, implying nearly 10% upside. The move follows strong Q1 results, with EPS of $2.91 and revenue of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context